β‐TrCP overexpression enhances cisplatin sensitivity by depleting BRCA1
Molecular Oncology, EarlyView.Low levels of β‐TrCP (Panel A) allow the accumulation of BRCA1 and CtIP, which facilitate the repair of cisplatin‐induced DNA damage via homologous recombination (HR) and promote tumor cell survival. In contrast, high β‐TrCP expression (Panel B) leads to BRCA1 and CtIP degradation, impairing HR repair, resulting in persistent DNA damage and apoptosis ...
Rocío Jiménez‐Guerrero +8 more
wiley +1 more source
Discretion and local health policy implementation: street-level bureaucrats and integrative and complementary therapies in Santos' local health units. [PDF]
Prim Health Care Res Dev, 2022 Macena A, Oliveira VE.
europepmc +1 more source
Molecular Oncology, EarlyView.Stemness properties, including quiescence, self‐renewal, and chemoresistance, are closely associated with leukemia relapse. Here, we demonstrate that DNA damage‐inducible transcript 4 (DDIT4) is induced in the hypoxic bone marrow niche and is essential for maintaining the stemness of AML1‐ETO9a leukemia cells.
Yishuang Li +12 more
wiley +1 more source
Current Treatments and New Possible Complementary Therapies for Epithelial Ovarian Cancer. [PDF]
Biomedicines, 2021 Garrido MP +5 more
europepmc +1 more source
Molecular Oncology, EarlyView.Proteomic and phosphoproteomic analyses were performed on lung adenocarcinoma (LUAD) tumors with EGFR, KRAS, or EML4–ALK alterations and wild‐type cases. Distinct protein expression and phosphorylation patterns were identified, especially in EGFR‐mutated tumors. Key altered pathways included vesicle transport and RNA splicing.
Fanni Bugyi +12 more
wiley +1 more source
Effectiveness of Complementary Therapies in Cancer Patients: A Systematic Review. [PDF]
Int J Environ Res Public Health, 2021 Guerra-Martín MD +2 more
europepmc +1 more source
The Effects of an Educational Intervention on Oncology Nurses' Attitude, Perceived Knowledge, and Self-Reported Application of Complementary Therapies [PDF]
, 2004 Rusti E. Hessig +2 more
openalex +1 more source
Molecular Oncology, EarlyView.Screening 166 FDA‐approved anticancer drugs identifies the aromatase inhibitor Exemestane as a synergistic partner of PARP inhibitor Olaparib in BRCA‐proficient triple‐negative breast cancer. Exemestane induces ROS‐mediated replication stress, enhancing DNA damage and apoptosis alongside Olaparib.
Nur Aininie Yusoh +5 more
wiley +1 more source
How best to capture the impact of complementary therapies in palliative care: A systematic review to identify and assess the appropriateness and validity of multi-domain tools. [PDF]
Palliat Med, 2022 Mitchinson L +8 more
europepmc +1 more source